Apratim Dutta

Apratim Dutta

Auto-generated profile, based on publicly available information

Apratim Dutta

Division of Molecular Medicine, Bose Institute, P-1/12, Calcutta Improvement Trust Scheme VII M, Kolkata 700054, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Science Signaling
Verified
Journal Article
Closed access
PDF file
ABApoorva Bhattacharya
Apoorva Bhattacharya
SMShravanti Mukherjee
Shravanti Mukherjee
PKPoulami Khan
Poulami Khan
SBShruti Banerjee
Shruti Banerjee
ADApratim Dutta
Apratim Dutta
TDTanya Das
Tanya Das
The high abundance of drug efflux pumps in cancer stem cells (CSCs) contributes to chemotherapy resistance. The transcriptional regulator SMAR1 suppresses CSC expansion in colorectal cancer, and increased abundance of SMAR1 is associated with better prognosis. Here, we found in breast tumors that the expression of SMAR1 was decreased in CSCs through the cooperative interaction of the pluripotency factors Oct4 and Sox2 with the histone deacetylase HDAC1. Overexpressing SMAR1 sensitized CSCs to chemotherapy through SMAR1-dependent recruitment of HDAC2 to the promoter of the gene encoding the drug efflux pump ABCG2. Treating cultured CSCs or 4T1 tumor-bearing mice with the nonsteroidal anti-inflammatory drug aspirin restored SMAR1 expression and ABCG2 repression and enhanced tumor sensitivity to doxorubicin. Our findings reveal transcriptional mechanisms regulating SMAR1 that also regulate cancer stemness and chemoresistance and suggest that, by restoring SMAR1 expression, aspirin might enhance chemotherapeutic efficacy in patients with stem-like tumors.

31 August 2023 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
SCSourio Chakraborty
Sourio Chakraborty
SMSumon Mukherjee
Sumon Mukherjee
UBUdit Basak
Udit Basak
SPSubhadip Pati
Subhadip Pati
ADApratim Dutta
Apratim Dutta
TDTanya Das
Tanya Das
Cancer stem cells (CSCs) are a small subpopulation of cells that drive the formation and progression of tumors. However, during tumor initiation, how CSCs communicate with neighbouring immune cells to overcome the powerful immune surveillance barrier in order to form, spread, and maintain the tumor, remains poorly understood. It is, therefore, absolutely necessary to understand how a small number of tumor-initiating cells (TICs) survive immune attack during (a) the “elimination phase” of “tumor immune-editing”, (b) the establishment of regional or distant tumor after metastasis, and (c) recurrence after therapy. Mounting evidence suggests that CSCs suppress the immune system through a variety of distinct mechanisms that ensure the survival of not only CSCs but also non-stem cancer cells (NSCCs), which eventually form the tumor mass. In this review article, the mechanisms via which CSCs change the immune landscape of the tissue of origin, which contains macrophages, dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, and tumor-infiltrating lymphocytes, in favour of tumorigenesis were discussed. The failure of cancer immunotherapy might also be explained by such interaction between CSCs and immune cells. This review will shed light on the critical role of CSCs in tumor immune evasion and emphasize the importance of CSC-targeted immunotherapy as a cutting-edge technique for battling cancer by restricting communication between immune cells and CSCs.

23 September 2025 in In Silico Research in Biomedicine
Verified
Journal Article
Open access
SCSourio Chakraborty
Sourio Chakraborty
UBUdit Basak
Udit Basak
ADApratim Dutta
Apratim Dutta
SMSumoyee Mukherjee
Sumoyee Mukherjee
GSGaurisankar Sa
Gaurisankar Sa
TDTanya Das
Tanya Das